extended-release guanfacine hydrochloride (SPD503)

DRUG2 trials

Sponsors

Shire, Maastricht University Medical Center

Conditions

Attention Deficit DisorderAttention-Deficit/Hyperactivity Disorder

Phase 3

Tolerability and Efficacy of AM and PM Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Children 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD) (The ADHD Tempo Study)

CompletedNCT00997984

ShireAttention-Deficit/Hyperactivity Disorder

Start: 2009-11-17End: 2010-10-09Updated: 2021-06-08

Extended-release Guanfacine Hydrochloride in Children/Adolescents With Attention-deficit/Hyperactivity

CompletedNCT03662763

Maastricht University Medical CenterAttention Deficit Disorder

Start: 2011-09-30End: 2013-12-31Updated: 2018-09-07

Related Papers

Does Guanfacine Extended Release Impact Functional Impairment in Children with Attention-Deficit/Hyperactivity Disorder? Results from a Randomized Controlled Trial.

2015-11-0118 citations